Determination of ranolazine in human plasma by LC-MS/MS and its application in bioequivalence study

Journal of Pharmaceutical and Biomedical Analysis

Volumn 48, Issue 5, 2008, Pages 1404-1410

  Bhaumik, Uttam ^a   Ghosh, Animesh ^a   Sarkar, Amlan Kanti ^a   Bose, Anirbandeep ^a   Selvan, P Senthamil ^a   Sengupta, Pinaki ^a   Chakraborty, Uday Sankar ^a   Ghosh, Debotri ^a   Pal, Tapan Kumar ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

Bioequivalence; Human plasma; LC MS MS; Quantification; Ranolazine

Indexed keywords

ARIPIPRAZOLE; RANOLAZINE; RANOZEX ER; UNCLASSIFIED DRUG;

ACCURACY; ADULT; ANALYTIC METHOD; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG STABILITY; FREEZE THAWING; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETER; MASS SPECTROMETRY; NORMAL HUMAN; PRECIPITATION; PRIORITY JOURNAL; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

ACETANILIDES; CHROMATOGRAPHY, LIQUID; DRUG STABILITY; ENZYME INHIBITORS; FREEZING; HUMANS; MOLECULAR STRUCTURE; PIPERAZINES; QUALITY CONTROL; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; THERAPEUTIC EQUIVALENCY; TIME FACTORS;

EID: 58149481502     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2008.09.033     Document Type: Article

References (14)

1. Tian L., Jiang J., Huang Y., Hua L., Liu H., and Li Y. J. Chromatogr. B 846 (2007) 346-350
2. Stone P.H., Gratsiansky N.A., Blokhin A., Huang I.Z., and Meng L. J. Am. Coll. Cardiol. 48 (2006) 566-575
3. Hale S.L., and Kloner R.A. J. Cardiovasc. Pharmacol. Ther. 11 (2006) 249-255
4. Fraser H., Belardinelli L., Wang L., Light P.E., Veigh J.J.M., and Clanachan A.S. J. Mol. Cell Cardiol. 41 (2006) 1031-1038
5. Mccormack J.G., Barr R.L., Wolff A.A., and Lopaschuk G.D. Circulation 93 (1996) 135-142
6. Chaitman B.R., Pepine C.J., Parker J.O., Skopal M.J., Chumakova G., Kuch J., Wang W., Skettino S.L., and Wolff A.A. JAMA 21 (2004) 309-316
7. Jerling M. Clin. Pharmacokinet. 45 (2006) 469-491
8. Penman A.D., Eadie J., Herron W.J., Reilly M.A., Rush W.R., and Liu Y. Rapid Commun. Mass Spectrom. 9 (1995) 1418-1430
9. Luo X., Zhai Z., Wu X., Shi Y., Chen L., and Li Y. J. Sep. Sci. 29 (2006) 164-171
10. Herron W.J., Eadie J., and Penman A.D. J. Chromatogr. A 712 (1995) 55-60
11. Liang Y., Xie L., Liu X.D., Chen W.D., Lu T., Xiong Y., and Wang G.J. Rapid Commun. Mass Spectrom. 20 (2006) 523-528
12. Zhong J., Liu X.Q., Chen Y., Zhao X.P., Wang Y.S., and Wang G.J. Chromatographia 63 (2006) 123-127
13. Food and Drug Administration of the United States, Guidance for Industry-Bioanalytical Method Validation, U.S. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), May 2001. http://www.fda.gov/cder/guidance/index.htm.
14. Nehal L.J., Alex S., William D.L., Jurgen V., and William F.D. J. Chromatogr. B 806 (2004) 289-293